Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer.

Peak TC, Panigrahi GK, Praharaj PP, Su Y, Shi L, Chyr J, Rivera-Chávez J, Flores-Bocanegra L, Singh R, Vander Griend DJ, Oberlies NH, Kerr BA, Hemal A, Bitting RL, Deep G.

Mol Carcinog. 2019 Nov 1. doi: 10.1002/mc.23129. [Epub ahead of print]

PMID:
31674708
2.

PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.

Shapovalova M, Lee JK, Li Y, Vander Griend DJ, Coleman IM, Nelson PS, Dehm SM, LeBeau AM.

Cancer Res. 2019 Nov 1;79(21):5668-5680. doi: 10.1158/0008-5472.CAN-19-2181. Epub 2019 Sep 17.

PMID:
31530569
3.

Single-cell RNA-Seq analysis identifies a putative epithelial stem cell population in human primary prostate cells in monolayer and organoid culture conditions.

McCray T, Moline D, Baumann B, Vander Griend DJ, Nonn L.

Am J Clin Exp Urol. 2019 Jun 15;7(3):123-138. eCollection 2019.

4.

Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.

Hu WY, Xu L, Chen B, Ou S, Muzzarelli KM, Hu DP, Li Y, Yang Z, Vander Griend DJ, Prins GS, Qin Z.

Prostate. 2019 Jul;79(10):1166-1179. doi: 10.1002/pros.23832. Epub 2019 May 28.

PMID:
31135075
5.

Sox2 Expression Marks Castration-Resistant Progenitor Cells in the Adult Murine Prostate.

McAuley E, Moline D, VanOpstall C, Lamperis S, Brown R, Vander Griend DJ.

Stem Cells. 2019 May;37(5):690-700. doi: 10.1002/stem.2987. Epub 2019 Feb 15.

6.

Self-Assembling Peptide Gels for 3D Prostate Cancer Spheroid Culture.

Hainline KM, Gu F, Handley JF, Tian YF, Wu Y, de Wet L, Vander Griend DJ, Collier JH.

Macromol Biosci. 2019 Jan;19(1):e1800249. doi: 10.1002/mabi.201800249. Epub 2018 Oct 15.

PMID:
30324687
7.

MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.

Bhanvadia RR, VanOpstall C, Brechka H, Barashi NS, Gillard M, McAuley EM, Vasquez JM, Paner G, Chan WC, Andrade J, De Marzo AM, Han M, Szmulewitz RZ, Vander Griend DJ.

Clin Cancer Res. 2018 Aug 1;24(15):3668-3680. doi: 10.1158/1078-0432.CCR-17-3673. Epub 2018 May 1.

8.

Exosomes secreted by placental stem cells selectively inhibit growth of aggressive prostate cancer cells.

Peak TC, Praharaj PP, Panigrahi GK, Doyle M, Su Y, Schlaepfer IR, Singh R, Vander Griend DJ, Alickson J, Hemal A, Atala A, Deep G.

Biochem Biophys Res Commun. 2018 May 23;499(4):1004-1010. doi: 10.1016/j.bbrc.2018.04.038. Epub 2018 Apr 9.

9.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13. Review.

10.

Magnetic Resonance Imaging and Molecular Characterization of a Hormone-Mediated Murine Model of Prostate Enlargement and Bladder Outlet Obstruction.

McAuley EM, Mustafi D, Simons BW, Valek R, Zamora M, Markiewicz E, Lamperis S, Williams A, Roman BB, Vezina C, Karczmar G, Oto A, Vander Griend DJ.

Am J Pathol. 2017 Nov;187(11):2378-2387. doi: 10.1016/j.ajpath.2017.07.014. Epub 2017 Aug 18.

11.

HOXB13 mutations and binding partners in prostate development and cancer: Function, clinical significance, and future directions.

Brechka H, Bhanvadia RR, VanOpstall C, Vander Griend DJ.

Genes Dis. 2017 Jun;4(2):75-87. doi: 10.1016/j.gendis.2017.01.003. Epub 2017 Feb 16.

12.

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG.

Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049.

13.

Contribution of Caudal Müllerian Duct Mesenchyme to Prostate Development.

Brechka H, McAuley EM, Lamperis SM, Paner GP, Vander Griend DJ.

Stem Cells Dev. 2016 Nov 15;25(22):1733-1741. Epub 2016 Oct 4.

14.

Dendritic Cells Coordinate the Development and Homeostasis of Organ-Specific Regulatory T Cells.

Leventhal DS, Gilmore DC, Berger JM, Nishi S, Lee V, Malchow S, Kline DE, Kline J, Vander Griend DJ, Huang H, Socci ND, Savage PA.

Immunity. 2016 Apr 19;44(4):847-59. doi: 10.1016/j.immuni.2016.01.025. Epub 2016 Mar 29.

15.

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.

Kregel S, Chen JL, Tom W, Krishnan V, Kach J, Brechka H, Fessenden TB, Isikbay M, Paner GP, Szmulewitz RZ, Vander Griend DJ.

Oncotarget. 2016 May 3;7(18):26259-74. doi: 10.18632/oncotarget.8456.

16.

Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.

Reyes EE, VanderWeele DJ, Isikbay M, Duggan R, Campanile A, Stadler WM, Vander Griend DJ, Szmulewitz RZ.

J Transl Med. 2014 Nov 26;12:313. doi: 10.1186/s12967-014-0313-z.

17.

The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.

Kregel S, Szmulewitz RZ, Vander Griend DJ.

Prostate. 2014 Nov;74(15):1530-43. doi: 10.1002/pros.22870. Epub 2014 Aug 31.

18.
19.

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.

Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD, Szmulewitz RZ.

Horm Cancer. 2014 Apr;5(2):72-89. doi: 10.1007/s12672-014-0173-2. Epub 2014 Mar 11.

20.
21.

Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing.

Zeng Y, Wodzenski D, Gao D, Shiraishi T, Terada N, Li Y, Vander Griend DJ, Luo J, Kong C, Getzenberg RH, Kulkarni P.

Cancer Res. 2013 Jul 1;73(13):4123-33. doi: 10.1158/0008-5472.CAN-12-1343. Epub 2013 May 10.

22.

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.

Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, Tom W, Paner GP, Szmulewitz RZ, Vander Griend DJ.

PLoS One. 2013;8(1):e53701. doi: 10.1371/journal.pone.0053701. Epub 2013 Jan 11.

23.

Growth kinetics of CD133-positive prostate cancer cells.

Reyes EE, Kunovac SK, Duggan R, Kregel S, Vander Griend DJ.

Prostate. 2013 May;73(7):724-33. doi: 10.1002/pros.22616. Epub 2012 Nov 8.

24.

Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression.

Chen JL, Li J, Kiriluk KJ, Rosen AM, Paner GP, Antic T, Lussier YA, Vander Griend DJ.

Clin Cancer Res. 2012 Aug 15;18(16):4291-302. doi: 10.1158/1078-0432.CCR-12-0373. Epub 2012 Jun 21.

25.

Building on the foundation of daring hypotheses: using the MKK4 metastasis suppressor to develop models of dormancy and metastatic colonization.

Knopeke MT, Ritschdorff ET, Clark R, Vander Griend DJ, Khan S, Thobe M, Shear JB, Rinker-Schaeffer CW.

FEBS Lett. 2011 Oct 20;585(20):3159-65. doi: 10.1016/j.febslet.2011.09.007. Epub 2011 Sep 12.

26.

Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling.

D'Antonio JM, Vander Griend DJ, Antony L, Ndikuyeze G, Dalrymple SL, Koochekpour S, Isaacs JT.

PLoS One. 2010 Jul 8;5(7):e11475. doi: 10.1371/journal.pone.0011475.

27.

Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells.

Vander Griend DJ, D'Antonio J, Gurel B, Antony L, Demarzo AM, Isaacs JT.

Prostate. 2010 Jan 1;70(1):90-9. doi: 10.1002/pros.21043.

28.

Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts.

Vander Griend DJ, Konishi Y, De Marzo AM, Isaacs JT, Meeker AK.

Prostate. 2009 Oct 1;69(14):1557-64. doi: 10.1002/pros.21001.

29.

Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.

Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR, Isaacs JT.

Mol Cancer Ther. 2009 May;8(5):1340-9. doi: 10.1158/1535-7163.MCT-08-1136. Epub 2009 May 5.

30.

DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer.

D'Antonio JM, Vander Griend DJ, Isaacs JT.

Endocr Relat Cancer. 2009 Jun;16(2):325-32. doi: 10.1677/ERC-08-0205. Epub 2009 Feb 24. Review.

31.

The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT.

Cancer Res. 2008 Dec 1;68(23):9703-11. doi: 10.1158/0008-5472.CAN-08-3084.

32.

Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation.

Vander Griend DJ, Litvinov IV, Isaacs JT.

Cell Cycle. 2007 Mar 15;6(6):647-51. Epub 2007 Mar 21. Review.

PMID:
17387277
33.

Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.

Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT.

Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15085-90. Epub 2006 Oct 2.

34.

Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells.

Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT.

Cancer Res. 2006 Sep 1;66(17):8598-607.

35.

The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.

Hickson JA, Huo D, Vander Griend DJ, Lin A, Rinker-Schaeffer CW, Yamada SD.

Cancer Res. 2006 Feb 15;66(4):2264-70.

36.

Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7.

Vander Griend DJ, Kocherginsky M, Hickson JA, Stadler WM, Lin A, Rinker-Schaeffer CW.

Cancer Res. 2005 Dec 1;65(23):10984-91.

37.

Metastasis suppressor genes: from gene identification to protein function and regulation.

Berger JC, Vander Griend DJ, Robinson VL, Hickson JA, Rinker-Schaeffer CW.

Cancer Biol Ther. 2005 Aug;4(8):805-12. Review.

PMID:
16082183
38.

Suppression of metastasis--a new function for known proteins.

Vander Griend DJ, Berger JC, Rinker-Schaeffer CW.

J Natl Cancer Inst. 2004 Mar 3;96(5):344-5. No abstract available.

PMID:
14996848
39.

A new look at an old problem: the survival and organ-specific growth of metastases.

Vander Griend DJ, Rinker-Schaeffer CW.

Sci STKE. 2004 Jan 13;2004(216):pe3. Review.

PMID:
14734785
40.

MKK4 and metastasis suppression: a marriage of signal transduction and metastasis research.

Robinson VL, Hickson JA, Vander Griend DJ, Dubauskas Z, Rinker-Schaeffer CW.

Clin Exp Metastasis. 2003;20(1):25-30. Review.

PMID:
12650604
41.

Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.

Yamada SD, Hickson JA, Hrobowski Y, Vander Griend DJ, Benson D, Montag A, Karrison T, Huo D, Rutgers J, Adams S, Rinker-Schaeffer CW.

Cancer Res. 2002 Nov 15;62(22):6717-23.

42.

Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.

Kim HL, Vander Griend DJ, Yang X, Benson DA, Dubauskas Z, Yoshida BA, Chekmareva MA, Ichikawa Y, Sokoloff MH, Zhan P, Karrison T, Lin A, Stadler WM, Ichikawa T, Rubin MA, Rinker-Schaeffer CW.

Cancer Res. 2001 Apr 1;61(7):2833-7.

Supplemental Content

Loading ...
Support Center